Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

June 5, 2019

Study Completion Date

May 20, 2022

Conditions
Condylomata Acuminata
Interventions
BIOLOGICAL

low dosage HPV Vaccine

Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

BIOLOGICAL

medium dosage HPV Vaccine

Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

BIOLOGICAL

high dosage HPV Vaccine

Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

BIOLOGICAL

Aluminium Adjuvant

Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Jun Zhang

OTHER

NCT02405520 - Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine | Biotech Hunter | Biotech Hunter